29 November 2021 - - US-based biopharmaceutical company Immunome, Inc. (NASDAQ: IMNM) has submitted an Investigational New Drug application to the US Food and Drug Administration for IMM-BCP-01, a three-antibody cocktail, for the treatment of SARS-CoV-2 (COVID-19), the company said.

IMM-BCP-01 is a three-antibody cocktail targeting non-overlapping regions of the Spike protein and elicits multi-modal activity in pre-clinical testing, including both ACE2 and non-ACE2 dependent neutralization, as well as inducing natural viral clearance mechanisms, such as complement activation and phagocytosis.

The cocktail significantly reduces viral load in lungs of the hamsters infected with SARS-CoV-2, and broadly neutralizes CDC current and former variants of concern, including the Delta variant, in in vitro testing.

Immunome's preclinical work includes investigational product safety testing. Immunome plans to initiate a placebo-controlled dose escalation study of IMM-BCP-01 in patients infected with SARS-CoV-2, pending FDA's acceptance of Immunome's IND submission.

This investigational work was funded by the US Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in collaboration with the Defense Health Agency. (Contract number: W911QY-20-9-0019)

Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated.

The company's initial focus is developing therapeutics to treat oncology and infectious diseases, including COVID-19.

Immunome's proprietary discovery engine identifies novel therapeutic antibodies and their targets by leveraging the highly educated components of the immune system, memory B cells, from patients whose bodies have learned to fight off their disease.